Literature DB >> 32448762

Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches.

Virginia Sandonís1, Estéfani García-Ríos2, Michael J McConnell2, Pilar Pérez-Romero3.   

Abstract

Cytomegalovirus (CMV) infection elicits a potent immune response that includes the stimulation of antibodies with neutralizing activity. Recent studies have focused on elucidating the role of neutralizing antibodies in protecting against CMV infection and disease and characterizing viral antigens against which neutralizing antibodies are directed. Here, we provide a synthesis of recent data regarding the role of neutralizing antibodies in protection against CMV infection/disease. We consider the role of humoral immunity in the context of the global CMV-specific immune response, and the implications that recent findings have for vaccine and antibody-based therapy design.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CMV-specific immune response; antibody-based therapeutics; cytomegalovirus; neutralizing antibodies; vaccine design

Mesh:

Substances:

Year:  2020        PMID: 32448762     DOI: 10.1016/j.tim.2020.04.003

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  8 in total

1.  Cross Strain Protection against Cytomegalovirus Reduces DISC Vaccine Efficacy against CMV in the Guinea Pig Model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  Viruses       Date:  2022-04-06       Impact factor: 5.818

2.  Targeted mutagenesis on PDGFRα-Fc identifies amino acid modifications that allow efficient inhibition of HCMV infection while abolishing PDGF sequestration.

Authors:  Svenja Feldmann; Immanuel Grimm; Dagmar Stöhr; Chiara Antonini; Peter Lischka; Christian Sinzger; Cora Stegmann
Journal:  PLoS Pathog       Date:  2021-03-29       Impact factor: 6.823

3.  Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus.

Authors:  Hang Su; Xiaohua Ye; Daniel C Freed; Leike Li; Zhiqiang Ku; Wei Xiong; Peng Gao; Xinli Liu; Diana Montgomery; Weifeng Xu; Amy S Espeseth; Dai Wang; Ningning Ma; Tong-Ming Fu; Ningyan Zhang; Zhiqiang An
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.

Authors:  Nina Reuter; Barbara Kropff; William J Britt; Michael Mach; Marco Thomas
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

5.  Deciphering the Potential Coding of Human Cytomegalovirus: New Predicted Transmembrane Proteome.

Authors:  Francisco J Mancebo; Marcos Parras-Moltó; Estéfani García-Ríos; Pilar Pérez-Romero
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

6.  Identification and Characterization of Epithelial Cell-Derived Dense Bodies Produced upon Cytomegalovirus Infection.

Authors:  Estéfani García-Ríos; María Josefa Rodríguez; María Carmen Terrón; Daniel Luque; Pilar Pérez-Romero
Journal:  Vaccines (Basel)       Date:  2022-08-12

7.  Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.

Authors:  Eleanor C Semmes; Itzayana G Miller; Courtney E Wimberly; Caroline T Phan; Jennifer A Jenks; Melissa J Harnois; Stella J Berendam; Helen Webster; Jillian H Hurst; Joanne Kurtzberg; Genevieve G Fouda; Kyle M Walsh; Sallie R Permar
Journal:  J Clin Invest       Date:  2022-08-15       Impact factor: 19.456

Review 8.  Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.

Authors:  Sara Scarpini; Francesca Morigi; Ludovica Betti; Arianna Dondi; Carlotta Biagi; Marcello Lanari
Journal:  Vaccines (Basel)       Date:  2021-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.